Sabratek purchasing controls for pre-filled syringes inadequate, FDA says in Dec. 12 warning letter.
This article was originally published in The Gray Sheet
Executive Summary
SABRATEK PURCHASING CONTROLS FOR IV FLUSH SYRINGES INADEQUATE, FDA SAYS in a Dec. 12 warning letter to the company. The agency cites Sabratek's Woburn, Massachusetts-based Rocap facility for failing to test incoming products such as syringe, heparin injection, and saline injection components. In addition, "suppliers of incoming product are neither audited nor under any written agreement." The warning letter follows an inspection conducted between Aug. 28 and Sept. 29.
You may also be interested in...
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.